Caring for life Better Health Affordable API
About Us
Dedicated to Hope, Healing, and Recovery.
Suzhou Pharmaserve Technology Co., Ltd., established in 2019, is a leading developer and global supplier of high-quality Active Pharmaceutical Ingredients (APIs). Headquartered in Suzhou Industrial Park, China, we specialize in delivering cost-effective and innovative solutions to pharmaceutical manufacturers worldwide. Our mission—Caring for Life, Better Health, Affordable API—guides our commitment to ensuring access to safe and affordable medicines for patients across the globe.
At Pharmaserve, we excel in the development, production, and marketing of APIs, with a strong focus on three core categories:
- Peptides: GLP-1 receptor agonists such as Semaglutide, Tirzepatide, and Liraglutide, which are pivotal in the treatment of Type 2 diabetes and obesity.
- Cephalosporins: High-quality APIs compliant with global regulatory standards.
- Advanced API Tech-Transfer Services: Enabling seamless production scaling and compliance for our partners.
We are recognized for adhering to rigorous international standards, including USP, EP, DMF, and CEP, ensuring the highest levels of safety, efficacy, and compliance.
With an extensive client base in 44 countries, including both regulated markets (USA, Europe, Japan) and emerging markets (Southeast Asia, Middle East, Latin America), we play a vital role in improving global healthcare accessibility. Our APIs empower generic pharmaceutical manufacturers to achieve faster time-to-market while maintaining cost efficiency.
Years Experienced
Clients
What We Do
Believe in us, we won’t let you down
GLP-1
GLP-1
Anti-biotics
Antibiotics
Tech-transfer
Tech-transfer
What is Ozempic® (Semaglutide)?
Semaglutide is a lipopeptide with a linear sequence of 31 amino acids. Like human Glucagon-like peptide-1 (GLP-1), it is used in combination with diet and exercise in the therapy of type 2 diabetes mellitus. It works as an anti-obesity agent, a neuroprotective agent, and an appetite depressant.
1. Ozempic 0.25mg
Aids in weight loss by controlling appetite, improving blood sugar levels, and promoting fat burning, making it an effective option for managing weight in obese patients.
2. Ozempic 0.5mg
Helps with weight loss by reducing hunger, improving blood sugar levels, and promoting fat burning, offering an effective solution for sustainable weight management.
3. Ozempic 1mg
Ozempic 1mg injection helps with weight loss and blood sugar control in Type 2 diabetes patients, improving insulin sensitivity and reducing appetite for effective long-term results.
4. Ozempic 2mg
Ozempic 2mg prescription helps manage Type 2 diabetes and promotes weight loss by improving blood sugar control and reducing appetite, offering effective results with regular use.
Semaglutide indications
Healing for a better world.
T2D(Type 2 Diabetes)
Semaglutide is a GLP-1 receptor agonist proven effective in treating Type 2 Diabetes (T2D). It helps control blood sugar levels by increasing insulin secretion, reducing glucose production, and delaying gastric emptying, leading to improved blood glucose control and weight loss.
Obesity
Semaglutide is also effective in treating obesity. By mimicking a natural hormone that regulates appetite, it helps reduce hunger, increase satiety, and promote weight loss. Clinical studies have shown significant reductions in body weight for individuals using Semaglutide alongside a healthy lifestyle.
MASH
Tirzepatide may improve fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH). A study found 73% of patients achieved MASH resolution without worsening fibrosis, and 59% had at least one stage improvement in fibrosis without worsening MASH after 52 weeks of treatment.
Alzheimer's disease
Novo Nordisk's semaglutide can reduce the risk of Alzheimer's disease by 40% to 70% in Type 2 diabetes patients compared to insulin. It also slows cognitive decline in mild Alzheimer's, with an 18% slower rate of decline at one year compared to the placebo group.
OAC
There is a strong linear correlation between obesity and obstructive sleep apnea (OSA), with excess weight being a major risk factor. Tirzepatide, a dual GLP-1 and GIP receptor agonist, has been shown to significantly reduce the severity of moderate to severe OSA in obese patients, improving both respiratory function and sleep quality.
Cardiology
The SUSTAIN 6 study is a key clinical trial, and the results show that Semaglutide can significantly reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes by 26%, especially the risk of non-fatal stroke by 39%.
CKD
T2D patients taking semaglutide were 24% less likely to experience the study's primary composite outcome of onset of kidney failure, decline in kidney function, and kidney-related or cardiovascular death. Patients treated with semaglutide were 20% less likely to die from any cause.
Why Choose Us
We are on the side of humanity
Pharmaserve supplies high-quality, affordable APIs to leading generic formulation manufacturers worldwide, enabling faster access to essential medicines for patients. We focus on improving access to complex therapies for chronic conditions like diabetes, cancer, and autoimmune diseases. With operations across the Belt and Road Initiative, Latin America, Japan, Korea, and emerging markets, we ensure responsive supply chains that adapt quickly to market changes, preventing shortages and meeting demand surges. Our commitment to operational efficiency, quality, and safety ensures reliable, timely product delivery.
Meet our clients
We work for them
At Pharmaserve, we work with trusted clients like AXXO, Chemo, IMCD, and Chemphar. These partners help us maintain high standards in supply chain, manufacturing, distribution, market insights, and logistics, ensuring we deliver quality products to the global pharmaceutical market.
CPHI China Visit us at Booth #W8C68
